Early-stage cancer is notoriously difficult and expensive to find.
But it doesn’t have to be.
Using nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – we have developed an approach that is showing tremendous promise in finding stage I cancer, when it is most treatable.
Our initial focus is on early detection of difficult-to-treat cancers, such as ovarian and lung, which today are often found too late to save lives.
"The difference between the Mercy approach and nucleic acid-based approaches is the huge increase in the abundance of the potential signal. I believe this novel approach may well crack the early detection problem. To be clear, the company has not demonstrated superiority to date – but its R&D program has moved rapidly and its clinical program is sound."